CD4 and cancer: In addition to the predominant CD4+ and CD8+ T cells expressing αβ TCRs, a subset of primarily CD4/CD8 double-negative T cells with γδ TCRs has garnered attention as a promising immune cell population for next-generation cancer immunotherapy.